16-Jan-2026 10:02 AM CST - Yahoo Finance Moderna's Q4 2025 Earnings: What to Expect Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.
16-Jan-2026 7:41 AM CST - Seeking Alpha Arbutus falls as patent dispute with Moderna hits EU snag Arbutus (ABUS) stock sinks as the European Patent Office revokes a patent that was subject to a legal dispute between the company and Moderna (MRNA). Read more here.
13-Jan-2026 3:43 PM CST - Yahoo Finance Adobe stock downgraded, Moderna surges on upbeat guidance Market Domination Overtime Host Josh Lipton tracks several of the day's top trending stock tickers, including Adobe's stock (ADBE) downgrade to Market Perform from Oppenheimer analysts, Moderna (MRNA) providing an upbeat update to its guidance,
13-Jan-2026 10:28 AM CST - Benzinga Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously communicated during its third-quarter earnings call. The company also improved its 2025 expected GAAP operating expenses by $200 million and increased its projected year-end cash balance to approximately $8.1 billion.
12-Jan-2026 7:01 AM CST - Seeking Alpha Moderna reiterates target of up to 10% revenue growth in 2026 Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large seasonal vaccine franchise. "We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations,
8-Jan-2026 7:58 PM CST - Yahoo Finance Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010 In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile.
Latest MRNA Trades by Congress Members
8-APR-2025 - Rob Bresnahan, PA (District 8) sold between $1,001 and $15,000.
16-Jan-2026 10:02 AM CST - Yahoo Finance Moderna's Q4 2025 Earnings: What to Expect Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.
16-Jan-2026 7:41 AM CST - Seeking Alpha Arbutus falls as patent dispute with Moderna hits EU snag Arbutus (ABUS) stock sinks as the European Patent Office revokes a patent that was subject to a legal dispute between the company and Moderna (MRNA). Read more here.
13-Jan-2026 3:43 PM CST - Yahoo Finance Adobe stock downgraded, Moderna surges on upbeat guidance Market Domination Overtime Host Josh Lipton tracks several of the day's top trending stock tickers, including Adobe's stock (ADBE) downgrade to Market Perform from Oppenheimer analysts, Moderna (MRNA) providing an upbeat update to its guidance,
13-Jan-2026 10:28 AM CST - Benzinga Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously communicated during its third-quarter earnings call. The company also improved its 2025 expected GAAP operating expenses by $200 million and increased its projected year-end cash balance to approximately $8.1 billion.
12-Jan-2026 7:01 AM CST - Seeking Alpha Moderna reiterates target of up to 10% revenue growth in 2026 Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large seasonal vaccine franchise. "We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations,
8-Jan-2026 7:58 PM CST - Yahoo Finance Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010 In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile.
